Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with chemotherapy and surgery within its marketing authorisation for treatment of resectable gastric or gastro-oesophageal junction cancer.
Status In progress
Decision Selected
Process STA 2018
ID number 2696

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
01 July 2021 - 29 July 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 June 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
24 January 2020 In progress. Topic is in progress

For further information on our processes and methods, please see our CHTE processes and methods manual